Articles from CurePSP

NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- CurePSP has announced its latest student fellowship recipients, totaling seven projects between the Urso Student Fellowship Grant and the Jim Atwood Neuroscience Student Fellowship Grant, awarded to projects advancing our understanding of progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and related diseases, as well as expanding the community of researchers dedicated to finding a cure. The fellowships aim to encourage students and trainees to pursue research in the field, making PSP and CBD long-term areas of research interest and furthering awareness and understanding of these diseases.

NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- CurePSP has announced its largest grant cycle to date, awarding a record number of Pathway and Pipeline Grants to researchers across North America and Europe. The grants include a $300,000 contribution from the Rainwater Charitable Foundation (RCF), one of the largest independent funders of primary tauopathy research. This collaboration reflects the growing momentum in the field and highlights CurePSP's commitment to building a robust network of investigators dedicated to understanding and treating progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and related disorders.

NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) -- CurePSP announced the latest recipients of the Collaborative Approaches to Resources, Education and Support (CARES) grants, awarding a total of $155,000 to four projects spanning seven leading medical institutions in the U.S. and Canada.

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The passing of Rev. Jesse L. Jackson, Sr. has cast a spotlight on progressive supranuclear palsy (PSP), one of the most misunderstood neurodegenerative diseases affecting Americans today. As tributes pour in, so too have questions about the disease he lived with for over a decade. First diagnosed with Parkinson's in 2017, Rev. Jackson did not receive his PSP diagnosis until 2024 — facing the same confusion and uncertainty that define the diagnostic journey for thousands of PSP families.